MicroPort
心通医疗

MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

PROFIT FORECAST
FOR THE FIRST HALF OF 2025 — SIGNIFICANT REDUCTION IN NET LOSS

This announcement is made by MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**" or "**our**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "**Board**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary review of the unaudited management accounts of the Group for the six months ended June 30, 2025 (the "**Reporting Period**") and an assessment of the latest information currently available to the Board, the Group is expected to record a net loss of no more than RMB10 million for the Reporting Period, representing a decrease of no less than 83% as compared to the net loss for the six months ended June 30, 2024. Such decrease in net loss is mainly attributable to:

(i) our sales of our VitaFlow Liberty® transcatheter aortic valve and retrievable delivery system in over 20 overseas countries/regions, with overseas revenue increasing by over 200% as compared to that for the six months ended June 30, 2024;

(ii) the steady advancement of commercialization of our AnchorMan® left atrial appendage closure system and its access system in the PRC, their CE Mark approval and subsequent commercialization in Europe during the Reporting Period, collectively contributing to incremental revenue;

(iii) the Group has further improved its operational efficiency by continuously optimizing resource allocation and actively controlling various expenses; and

(iv) a gain on deemed disposal of the equity interest of 4C Medical Technologies, Inc. ("**4C Medical**"), an associate of the Group, following the completion of series D financing of 4C Medical.

As the Company is still in the process of finalising the interim results of the Group for the six months ended June 30, 2025, the information contained in this announcement is only based on a preliminary assessment of the unaudited consolidated management accounts and relevant revenue and expense estimates made available to the Board as of the date of this announcement, which have not been audited or reviewed by the Company's auditors or reviewed by the audit committee of the Company, and the above information may be subject to adjustments. Further details of the Group's financial information will be disclosed in the Group's interim results announcement for the six months ended June 30, 2025, which is expected to be published in August 2025 according to the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, August 7, 2025

As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.